Life Science Company News

The urticaria drugs market will register a CAGR of over 10% by 2022

NEW YORK, March 20, 2019 /PRNewswire/ -- About this market
Urticaria is a vastly prevalent disorder resulting in high medical consultations globally. The increase in risk factors for urticaria like latent infectious, chronic inflammatory diseases, autoreactivity and alcohol consumption. Though the incident is increasing, and it is negatively impacting the quality of life of the people, most patients are undertreated due to challenges in affordability of drugs and low access to healthcare due to social stigma. Technavio's analysts have predicted that the urticaria drugs market will register a CAGR of over 10% by 2022.

Read the full report: https://www.reportlinker.com/p05745761/?utm_source=PRN

Market Overview
Guidelines for management of urticaria patients
The management guidelines include clinical classification, etiology, investigations, diagnosis, treatment guidance along with special sections on children suffering from urticaria and the use of antihistamines in pregnant women or breastfeeding women.
High cost of urticaria management
The high medication costs along with the indirect costs are expected to put low- income patients at danger for suboptimal treatment and an increased burden due to poorly controlled disease.
For the detailed list of factors that will drive and challenge the growth of the urticaria drugs market during the 2018-2022, view our report.

Competitive Landscape
The global urticaria drugs market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05745761/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-urticaria-drugs-market-will-register-a-cagr-of-over-10-by-2022-300815810.html

SOURCE Reportlinker

- 21 Mar 2019
Back to overview

Enhance your business development with Biotechgate